HY-B1642R Search Results


ethotoin  (MedChemExpress)
94
MedChemExpress ethotoin
A , B Top-ranking drugs similar to necrostatin-1. Drugs sharing structural similarity were ranked from the DrugBank dataset (A), and the top 7 drugs and their similarity values to Nec-1 are displayed (B). C Comparison of docking scores <t>for</t> <t>phensuximide</t> (Phen), <t>ethotoin,</t> and sumatriptan with the RIPK1 kinase domain and their corresponding chemical structures. D Molecular docking analysis depicting the binding modes of Nec-1, Phen, ethotoin and sumatriptan within the RIPK1 kinase domain. Key interactions, including hydrogen bonds and π‒π stacking interactions, are highlighted in the upper panel. Amino acids of RIPK1 within 4Å are displayed with ligands in the lower panel, with the properties of the amino acids and their interactions with ligands annotated in the accompanying box. E Molecular dynamics (MD) simulation showing the root-mean-square deviations (RMSDs) of the RIPK1 kinase domain and ligands necrostatin-1 (left panel) and phensuximide (right panel).
Ethotoin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ethotoin/product/MedChemExpress
Average 94 stars, based on 1 article reviews
ethotoin - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


A , B Top-ranking drugs similar to necrostatin-1. Drugs sharing structural similarity were ranked from the DrugBank dataset (A), and the top 7 drugs and their similarity values to Nec-1 are displayed (B). C Comparison of docking scores for phensuximide (Phen), ethotoin, and sumatriptan with the RIPK1 kinase domain and their corresponding chemical structures. D Molecular docking analysis depicting the binding modes of Nec-1, Phen, ethotoin and sumatriptan within the RIPK1 kinase domain. Key interactions, including hydrogen bonds and π‒π stacking interactions, are highlighted in the upper panel. Amino acids of RIPK1 within 4Å are displayed with ligands in the lower panel, with the properties of the amino acids and their interactions with ligands annotated in the accompanying box. E Molecular dynamics (MD) simulation showing the root-mean-square deviations (RMSDs) of the RIPK1 kinase domain and ligands necrostatin-1 (left panel) and phensuximide (right panel).

Journal: Cell Death & Disease

Article Title: FDA-approved phensuximide inhibits RIPK1-dependent immunogenic cell death

doi: 10.1038/s41419-025-07754-2

Figure Lengend Snippet: A , B Top-ranking drugs similar to necrostatin-1. Drugs sharing structural similarity were ranked from the DrugBank dataset (A), and the top 7 drugs and their similarity values to Nec-1 are displayed (B). C Comparison of docking scores for phensuximide (Phen), ethotoin, and sumatriptan with the RIPK1 kinase domain and their corresponding chemical structures. D Molecular docking analysis depicting the binding modes of Nec-1, Phen, ethotoin and sumatriptan within the RIPK1 kinase domain. Key interactions, including hydrogen bonds and π‒π stacking interactions, are highlighted in the upper panel. Amino acids of RIPK1 within 4Å are displayed with ligands in the lower panel, with the properties of the amino acids and their interactions with ligands annotated in the accompanying box. E Molecular dynamics (MD) simulation showing the root-mean-square deviations (RMSDs) of the RIPK1 kinase domain and ligands necrostatin-1 (left panel) and phensuximide (right panel).

Article Snippet: Phensuximide, Methsuximide, Ethotoin and Ethosuximide were purchased from MedChemExpress.

Techniques: Comparison, Binding Assay

A Chemical structure of ethotoin (left panel). HT-29 cells were pretreated with the indicated concentrations of ethotoin for 1 h and then treated with TSZ for 5 h. Cell viability was analyzed by the MTT assay (middle panel). Images are representative of at least three independent experiments (right panel). B HT-29 cells were pretreated with ethotoin (200 μM) for 1 h and then treated with TSZ. Cytotoxicity was measured by the fluorescence intensity of Sytox Orange (left panel). Representative images of cell death were taken at 5 h (right panel). C , D Chemical structures of Phen and ethosuximide (C, left panel). HT-29 cells were pretreated with the indicated concentrations of ethosuximide for 1 h and then treated with TSZ. Cytotoxicity was determined by the LDH assay (C, middle panel), representative images of cell death (C, right panel) or the fluorescence intensity of Sytox Orange (D).

Journal: Cell Death & Disease

Article Title: FDA-approved phensuximide inhibits RIPK1-dependent immunogenic cell death

doi: 10.1038/s41419-025-07754-2

Figure Lengend Snippet: A Chemical structure of ethotoin (left panel). HT-29 cells were pretreated with the indicated concentrations of ethotoin for 1 h and then treated with TSZ for 5 h. Cell viability was analyzed by the MTT assay (middle panel). Images are representative of at least three independent experiments (right panel). B HT-29 cells were pretreated with ethotoin (200 μM) for 1 h and then treated with TSZ. Cytotoxicity was measured by the fluorescence intensity of Sytox Orange (left panel). Representative images of cell death were taken at 5 h (right panel). C , D Chemical structures of Phen and ethosuximide (C, left panel). HT-29 cells were pretreated with the indicated concentrations of ethosuximide for 1 h and then treated with TSZ. Cytotoxicity was determined by the LDH assay (C, middle panel), representative images of cell death (C, right panel) or the fluorescence intensity of Sytox Orange (D).

Article Snippet: Phensuximide, Methsuximide, Ethotoin and Ethosuximide were purchased from MedChemExpress.

Techniques: MTT Assay, Fluorescence, Lactate Dehydrogenase Assay